Vivos Therapeutics (VVOS) Interest Expenses (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Interest Expenses data on file, last reported at -$1.4 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 4848.28% year-over-year to -$1.4 million in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 4848.28% decrease from a year earlier, with the FY2025 full-year figure at -$2.0 million, down 109.36% from the prior year.
• Interest Expenses for Q1 2026 stood at -$1.4 million, down from $800000.0 in the prior quarter.
• Over the last five years, Interest Expenses for VVOS reached as high as $2.7 million in Q2 2023 and fell as low as -$1.4 million in Q1 2026.
• Historically, Interest Expenses has averaged $547352.9 across 5 years, with a median of $493000.0 in 2024.
• Across the five-year window, Interest Expenses jumped 39900.0% in 2025 and sank 4848.28% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $436000.0 in 2022, then surged by 48.85% to $649000.0 in 2023, then slumped by 99.69% to $2000.0 in 2024, then soared by 39900.0% to $800000.0 in 2025, then plunged by 272.12% to -$1.4 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were -$1.4 million in Q1 2026, $800000.0 in Q4 2025, and -$338000.0 in Q3 2025.